Idarucizumab for Dabigatran Reversal.
By C. Pollack, P. Reilly, J. Eikelboom, S. Glund, P. Verhamme, R. Bernstein, R. Dubiel, M. Huisman, E. Hylek, P. Kamphuisen and 8 more. New England Journal of Medicine, 2015
1,551 citations recorded by the source corpus.
BACKGROUND Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran. METHODS We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B). The primary end point was the maximum percentage reversal of the anticoagulant effect of dabigatran within 4 hours after the administration of idarucizumab, on the basis of the determination at a central laboratory of the dilute thrombin time or ecarin clotting time. A key secondary end point was the restoration of hemostasis. RESULTS This interim analysis included 90 patients who received idarucizumab (51 patients in group A and 39 in group B). Among 68 patients with an elevated dilute thrombin time and 81 with an elevated ecarin clotting time at baseline, the median maximum percentage reversal was 100% (95% confidence interval, 100 to 100). Idarucizumab normalized the test results in 88 to 98% of the patients, an effect that was evident within minutes. Concentrations of unbound dabigatran remained below 20 ng per milliliter at 24 hours in 79% of the patients. Among 35 patients in group A who could be assessed, hemostasis, as determined by local investigators, was restored at a median of 11.4 hours. Among 36 patients in group B who underwent a procedure, normal intraoperative hemostasis was reported in 33, and mildly or moderately abnormal hemostasis was reported in 2 patients and 1 patient, respectively. One thrombotic event occurred within 72 hours after idarucizumab administration in a patient in whom anticoagulants had not been reinitiated. CONCLUSIONS Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947.).
Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine
View Paper: https://www.semanticscholar.org/paper/b4122c40b8c9de50f8469a1c0dbcae65b57af3fb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, methodology): “Phase I safety studies and interim analysis of RE-VERSE AD study published [170, 171, 173, 434] Idarucizumab immediately and safely reversed dabigatran and normal hemostasis was achieved in 90 % of patients who underwent procedures following reversal Neurocrit Care”
- Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition) (2018, positive): “A recent clinical trial in patients with bleeding or requiring urgent surgery demonstrated that idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.(174) In October 2015, idarucizumab was approved by the FDA to be used in adult”
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “body fragment that binds dabigatran and rapidly and dose-dependently reverses its effects without over-correction or thrombin generation.(475) Andexanet alpha, a modified recombinant human factor Xa that lacks enzymatic activity, reverses the anticoagulant activity of factor Xa antagonists in health”
- The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition (2016, neutral): “) should be initiated [624, 625], or if unavailable, preoperative haemodialysis considered [626, 627].”